Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

This multicenter, randomized, double-blind, placebo-controlled induction study evaluated the efficacy and safety of risankizumab for moderately to severely acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-01-16